Viragen, Inc.
 

 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 13, 2005

VIRAGEN, INC.

(Exact name of registrant as specified in its charter)
         
Delaware   001-15823   59-2101668
         
(State or other jurisdiction of
incorporation) 		  (Commission File Number)   (IRS Employer
Identification No.)
         
865 SW 78th Avenue, Suite 100, Plantation, Florida   33324
     
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (954) 233-8746

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 

 

Item 8.01 Other Events.

     On May 18, 2005, the Company announced that it had elected not to exercise an exclusive option to license the University of Miami’s proprietary IEP 11 peptide. As a result, the option has expired and Viragen has discontinued all development activity for this compound, which was being researched as a potential cancer therapeutic.

     On May 18, 2005, Viragen issued a press release announcing the matters discussed above. The full text of the press release is attached as Exhibit 99.1 to this report.

Item 9.01 Financial Statements and Exhibits

     (c) Exhibits.

          99.1 Press release dated May 18, 2005

2

 

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
  VIRAGEN, INC.
 		  
Date: May 18, 2005  By:   /s/ Dennis W. Healey    
    Dennis W. Healey   
    Executive Vice President and
Principal Financial Officer 		  
 

3